2018
Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial
Edelman EJ, Moore BA, Holt SR, Hansen N, Kyriakides TC, Virata M, Brown ST, Justice AC, Bryant KJ, Fiellin DA, Fiellin LE. Efficacy of Extended-Release Naltrexone on HIV-Related and Drinking Outcomes Among HIV-Positive Patients: A Randomized-Controlled Trial. AIDS And Behavior 2018, 23: 211-221. PMID: 30073637, PMCID: PMC6476298, DOI: 10.1007/s10461-018-2241-z.Peer-Reviewed Original ResearchConceptsHIV-positive patientsHeavy drinking daysVACS Index scoreXR-NTXART adherenceDrinking daysIndex scoreUndetectable HIV viral loadCD4 cell countExtended-release naltrexoneDouble-blind placeboHIV viral loadRandomized-controlled trialDrinking outcomesHIV biomarkersSecondary outcomesHIV outcomesPrimary outcomeViral loadAntiretroviral adherenceClinical trialsCell countAlcohol treatmentHIVPatients
1998
Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy
Weiss M, Rodby R, Justice A, Hricik D, Group T. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Kidney International 1998, 54: 193-202. PMID: 9648079, DOI: 10.1046/j.1523-1755.1998.00982.x.Peer-Reviewed Original ResearchConceptsC-reactive proteinProtein-bound pentosidineDiabetic nephropathyInterleukin-6Serum creatinineFree pentosidineMonocyte/macrophage activationAdvanced glycation end product pentosidineBaseline disease activityDegree of proteinuriaSubgroup of patientsImmune activation responseProportional hazards methodsDisease activityInflammatory markersCreatinine levelsRenal functionDiabetes mellitusSerum levelsDiabetic complicationsProgression rateGroup trialsHazards methodsMacrophage activationNephropathy